Serono's Serostim: Changing Criteria for European Biologics Approval
Serono's appealing the European regulator's negative opinion on AIDS-wasting treatment Serostim reflects more than the product's importance to the Swiss group. The rift highlights confusion surrounding Europe's biologics approval process and reinforces fears that cost-conscious Europe is not rewarding innovation.
You may also be interested in...
Recent excitement around exosomes underscores their potential to solve drug delivery challenges that have limited the power and applicability of the biopharma industry’s growing arsenal of therapeutic modalities.
Datamonitor Healthcare's five-year review of initial public offerings of CNS-focused companies shows that they held their own compared with other biopharma sectors. The markets rewarded pain and neurodegenerative disease-focused players in particular. Step-up multiples in CNS IPOs slightly outpaced those for other biotechs.
Bayer AG may more often make headlines for its deal-making in consumer health and agriculture, but the massive German conglomerate sees oncology drugs as a key engine of future success within its high-growth pharmaceuticals business. A Q&A with Robert LaCaze, EVP of Bayer's new Oncology Strategic Business Unit.